COMMUNIQUÉS West-GlobeNewswire

Coherus Announces Repurchase of Approximately $170 Million of Convertible Notes
01/04/2025
– Remaining $60 Million of outstanding convertible notes to be repurchased post-close of pending UDENYCA divestiture – REDWOOD CITY, Calif., April 01, 2025 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus” or the [...]
Marker Therapeutics to Present at Canaccord Genuity’s Horizons in Oncology Conference
01/04/2025
HOUSTON, April 01, 2025 (GLOBE NEWSWIRE) -- MARKER THERAPEUTICS, INC. (Nasdaq: MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies for the treatment of [...]
electroCore to Participate at the Needham Virtual Healthcare Conference
01/04/2025
ROCKAWAY, N.J., April 01, 2025 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that management will participate at the Needham [...]
Avadel Pharmaceuticals to Present at the 24th Annual Needham Healthcare Conference
01/04/2025
DUBLIN, April 01, 2025 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that members of management will [...]
Merus to Participate in a Fireside Chat at the 24th Annual Needham Virtual Healthcare Conference
01/04/2025
UTRECHT, The Netherlands and CAMBRIDGE, Mass., April 01, 2025 (GLOBE NEWSWIRE) -- Merus N.V . (Nasdaq: MRUS), an oncology company developing innovative, full-length multispecific antibodies and antibody drug conjugates [...]
FeraMAXᴹᴰ est la marque de supplément de fer que les pharmaciens et les médecins au Canada recommandent le plus souvent depuis dix années consécutives
01/04/2025
MISSISSAUGA, Ontario, 01 avr. 2025 (GLOBE NEWSWIRE) -- BioSyent Inc. (« BioSyent », titre à la Bourse de croissance TSX : RX) est fière d’annoncer que FeraMAX MD est la marque de supplément de fer la plus recommandée au [...]
Merus participera à une discussion informelle lors de la 24e conférence annuelle Needham Virtual Healthcare
01/04/2025
UTRECHT, Pays-Bas et CAMBRIDGE, État du Massachussets, 01 avr. 2025 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq : MRUS), entreprise spécialisée en oncologie développant des anticorps de pleine longueur multispécifiques et [...]
FeraMAX® Named #1 Recommended Iron Supplement in Canada by Pharmacists and Physicians for Tenth Consecutive Year
01/04/2025
MISSISSAUGA, Ontario, April 01, 2025 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, TSX Venture: RX) is pleased to announce that FeraMAX ® is the #1 recommended iron supplement brand in Canada, based on a national [...]
Medera Presented Updated Results from First-In-Human Gene Therapy Trial for Heart Failure with Preserved Ejection Fraction at 2025 HFpEF Summit
01/04/2025
BOSTON, April 01, 2025 (GLOBE NEWSWIRE) -- Medera Inc. (“Medera”), a clinical-stage biopharmaceutical company focused on targeting cardiovascular diseases by developing a range of next-generation therapeutics, today [...]
Certara Expands the Simcyp™ Simulator Platform Advancing Biopharmaceutics, Drug-Drug Interaction & Biologic Capabilities
01/04/2025
Updates strengthen Certara’s position as a leader of PBPK modeling in drug development to advance regulatory decision-making RADNOR, Pa., April 01, 2025 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader [...]
Advanced Medical Balloons presents results from HYDRA-PMCF study of hygh-tec®, demonstrating high performance and safety
01/04/2025
HYDRA-PMCF-study evaluated hygh-tec®, a new polyurethane fecal management system hygh-tec® showed a high level of sealing performance (no leakage in 89.3%) and was safe to use (94.2% no signs of infection; GLOBIAD score [...]
Lantern Taps Industry Veteran for Labor, Union & Trust
01/04/2025
Specialty Care leader looks to extend its success in commercial market by supporting growth in Union vertical DALLAS, April 01, 2025 (GLOBE NEWSWIRE) -- Lantern , the Specialty Care Platform connecting 6 million members [...]
RESTEM to Participate in Jones Las Vegas Technology and Innovation Conference
01/04/2025
MIAMI, April 01, 2025 (GLOBE NEWSWIRE) -- RESTEM – a clinical-stage biotechnology company that develops off-the-shelf, next-generation cell therapies designed to modulate the immune system, today announced its [...]
Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
01/04/2025
CHARLESTOWN, Mass., April 01, 2025 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company”), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today [...]
Pacira BioSciences to Participate in Fireside Chat at the 24th Annual Needham Virtual Healthcare Conference
01/04/2025
BRISBANE, Calif., April 01, 2025 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, [...]
Collegium to Participate in 24th Annual Needham Virtual Healthcare Conference
01/04/2025
STOUGHTON, Mass., April 01, 2025 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) today announced that management will participate in a fireside chat at the 24 th Annual Needham Healthcare Conference [...]
Scientific Industries to Host Fiscal Year 2024 Financial Results Investor Call on April 1, 2025
01/04/2025
Investor Call to be held at 11:00 AM Eastern Time BOHEMIA, N.Y., April 01, 2025 (GLOBE NEWSWIRE) -- Scientific Industries, Inc. (OTCQB: SCND), a life sciences tool provider, and a developer of digitally simplified [...]
Inspire Medical Systems, Inc. to Report First Quarter 2025 Financial Results on May 5, 2025
01/04/2025
MINNEAPOLIS, April 01, 2025 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE: INSP) (Inspire) will release financial results for the first quarter 2025 after the close of trading on Monday, May 5. Inspire’s [...]
Avalyn Completes Successful Phase 1 Clinical Trials of AP02, its Novel Inhaled Formulation of Nintedanib, Preparing for Phase 2 Development in Idiopathic Pulmonary Fibrosis
01/04/2025
Topline data from the single- and multiple-ascending dose studies confirmed safety and favorable tolerability profile of AP02 at all dose levels Full safety, tolerability, and pharmacokinetics data to be presented at [...]

Pages